December 2016
-
GSK and AstraZeneca have announced that the two companies, along with the University of Manchester, are working together to create the Manchester Collaborative Centre for Inflammation Research (MCCIR) to facilitate translational research in inflammatory diseases,… Read more . . .
-
According to reports, Takeda Pharmaceutical is looking to buy Swiss pharma company Nycomed, which manufactures several OINDPs, including the Alvesco ciclesonide MDI and Omnaris ciclesonide nasal spray. Nycomed is also developing a ciclesonide HFA nasal… Read more . . .
-
Five days after its end of review meeting with the FDA on May 4 regarding its Afrezza inhaled insulin, MannKind Corporation held a conference call to update its progress and financial situation. During the call,… Read more . . .
-
Software companies S-Matrix and CI Informatics have announced that they will provide their Fusion Inhaler Testing (FIT) software free of charge to universities in the UK. Any UK university that conducts cascade impaction studies is… Read more . . .
-
Over the past 8 months, says API developer and manufacturer Hovione, its facilities have undergone a total of 6 inspections by the US FDA, the Japanese PMDA, and the Portuguese authorities. Pre-approval inspections for 2… Read more . . .
-
MicroDose Therapeutx, Monmouth Junction, NJ, is looking for a Senior Aerosol Scientist with a minimum of 8 years working with aerosols. Qualified candidates will possess the following: Minimum of 8 years working with aerosols Extensive… Read more . . .
-
MicroDose Therapeutx, Monmouth Junction, NJ, is looking for a Director of Engineering. This position will be responsible for providing innovation driven leadership for the Engineering Group which is comprised of both Mechanical Engineering and Electronics… Read more . . .
-
An article in the May 5 issue of the New England Journal of Medicine finds leukotriene-receptor antagonists (LTRAs) such as montelukast (Singulair) as effective as ICS as a first-line treatment for asthma and as effective… Read more . . .
-
On the final day of RDD Europe 2011 in Berlin, most of the focus turned to the abbreviated impactor method (AIM) and efficient data analysis (EDA), but the first session of the morning was devoted… Read more . . .
-
Rigel Pharmaceuticals says it will assume development responsibilities for R343, an inhaled syk inhibitor for the treatment of allergic asthma after Pfizer returned all rights to the program. Pfizer had licensed R343, along with other… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland